Vai alla homepage

Pagina 4 - I migliori medici di Chemioterapia - TOP-140medici

Il contenuto è conforme alla Politica editoriale di Bookimed ed è revisionato da medici

Fahad Mawlood

Mustafa Serkan Alemdar

  • 4.5 Buono 6 recensioni
  • 20 anni di esperienza
  • Turchia, Adalia, Medical Park Antalya Hospital Complex
  • Education and Specialization

    • 2006: Kocaeli University Faculty of Medicine
    • 2014: Akdeniz University Faculty of Medicine, Internal Medicine
    • 2018: Akdeniz University Faculty of Medicine, Medical Oncology

    Experience

    • 2006 - 2008: Konya Derebucak District Hospital
    • 2009 - 2015: Akdeniz University Hospital
    • 2015: Antalya Kaş State Hospital
    • 2015 - 2016: İnönü University Faculty of Medicine
    • 2016 - 2021: Akdeniz University Hospital
    • 2021 - 2023: Antalya Training and Research Hospital
  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Mehmet Faik Cetindag

  • 4.6 Eccellente 473 recensioni
  • 35 anni di esperienza
  • Turchia, Istanbul, Medipol Mega University Hospital
  • Dr. Mehmet Faik Çetindağ is a highly experienced oncologist, specializing in radiation oncology with over 30 years of practice. His research and publications, with emphasis on head and neck cancers, are notable. He is proficient in a wide range of procedures including Chemotherapy, Radiotherapy, Target Therapy, Immunotherapy, Intraoperative Chemotherapy, Gamma Knife, Intrabeam (Intraoperative radiotherapy), and TrueBeam IMRT RadioTherapy.
  • Mostra di più
Informazioni

Christiane Thallinger

  • 4.7 Eccellente 155 recensioni
  • 27 anni di esperienza
  • Austria, Vienna, Wiener Privatklinik
  • Dr. Christiane Thallinger is an Austrian dermatologist and venereologist. She focuses on skin cancer and oncologic dermatology. She began her medical career in 1999. She completed dermatology training at the Medical University of Vienna. She later served as a senior physician in its Department of Dermatology.

    Her expertise includes diagnosis and treatment of melanoma, basal cell carcinoma, and squamous cell carcinoma. She performs dermatosurgery, cryotherapy, and photodynamic therapy. She also manages skin side effects caused by cancer treatment.

    She is active in patient care and academic research. She is recognized for her patient-centered approach and for advancing dermatologic oncology in Austria.

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Sema Anak

  • 4.6 Eccellente 473 recensioni
  • 45 anni di esperienza
  • Turchia, Istanbul, Medipol Mega University Hospital
  • Pediatric Hematology and Oncology / Pediatric Oncology

Informazioni

Walter Klepetko

  • 4.7 Eccellente 155 recensioni
  • 48 anni di esperienza
  • Austria, Vienna, Wiener Privatklinik
  • Prof. Dr. Walter Klepetko is a world-renowned thoracic surgeon and head of the Department of Thoracic Surgery of the Medical University of Vienna, Vienna General Hospital, and Wiener Privatklinik. He is credited with initiating the Vienna Lung Transplant Program and co-developing the surgical technique of extracorporeal membrane oxygenation (ECMO). In 2018, he successfully performed a lung transplant on three-time Formula 1 world champion Niki Lauda.
  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Sonnenblick Amir

  • 4.5 Buono 156 recensioni
  • 19 anni di esperienza
  • Israele, Tel Aviv-Giaffa, Sourasky Medical Center (Ichilov)
  • Dr. Sonnenblick Amir is a renowned surgical oncologist with a specialized focus in breast cancer. He has received several accolades for his work, including the ESMO Breast Cancer Translational Research Award and ISCORT Best Paper of the Year Award twice. He is known for his involvement in important clinical trials such as 'Aphinity' and 'Olympia'. He has also contributed to over 30 national and international scientific meetings and his research has been published on numerous occasions.
  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Wolfgang Köstler

  • 4.7 Eccellente 155 recensioni
  • 22 anni di esperienza
  • Austria, Vienna, Wiener Privatklinik
  • Univ.-Prof. Dr. Wolfgang Johannes Köstler is a board-certified specialist for Internal Medicine, Hematology/Oncology, and Intensive Care Medicine who specializes in hematology & internal oncology, intensive care medicine. He is one of the top-rated breast cancer and sarcoma oncologist specialists and has extensive experience in the field and has received degrees from the Medical University of Vienna and the Weizmann Institute of Science. He has also had special training at Memorial Sloan-Kettering Cancer Center and Royal Prince Alfred Hospital.

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Tahsin Ozatli

  • Medico leader per Chemioterapia
  • 4.3 Buono 18 recensioni
  • 2016 anni di esperienza
  • Turchia, Istanbul, Istinye University Liv Hospital Bahcesehir
  • Oncologist
Chemioterapia
$2,000 - $9,000
Informazioni

Phd Viola Fox

  • Medico leader per Chemioterapia
  • 4.7 Eccellente 61 recensioni
  • 14 anni di esperienza
  • Germania, Solingen, Medical Center in Solingen
  • Esperta in chemioterapia e immunoterapia – La dottoressa Viola Fox, PhD, guida la Clinica di Ematologia, Oncologia e Cure Palliative presso BKZ Solingen.

    • Specialista in ematologia, oncologia e immunologia dal 2011
    • Qualificata in genetica e diagnostica molecolare
    • Ricercatrice attiva nei trattamenti delle malattie emato-oncologiche
    • Membro di società di ricerca sul cancro tedesche e americane
  • Mostra di più
Informazioni

Lu Peihua

  • 3 Buono 1 recensioni
  • 31 anni di esperienza
  • Cina, Pechino, Lu Daopei Hematology Hospital
Visita dal medico
Prezzo su richiesta
Informazioni

Séverine Iborra

  • 4.7 Eccellente 61 recensioni
  • 19 anni di esperienza
  • Germania, Solingen, Medical Center in Solingen
  • La Dott.ssa Séverine Iborra dirige il Dipartimento di Ginecologia e Ostetricia presso lo Städtisches Klinikum Solingen, specializzandosi in oncologia ginecologica con particolare attenzione ai trattamenti per il cancro al seno.

    • Certificata in oncologia ginecologica e ostetricia specialistica
    • Esperta in tecniche mini-invasive, inclusa la chirurgia robotica
    • Membro attivo delle principali società ginecologiche tedesche
    • Ha pubblicato ampiamente nella ricerca sull'oncologia molecolare
  • Mostra di più
Informazioni

Cemil Bilir

  • Medico leader per Chemioterapia
  • 5 Eccellente 1 recensioni
  • 21 anni di esperienza
  • Turchia, Istanbul, VM Medical Park Pendik Hospital
  • Education & Expertise

    • 1998 to 2004 – Istanbul University, Istanbul Faculty of Medicine
    • 2005 to 2009 – Düzce University, Internal Medicine Specialization
    • 2009 to 2010 – Beytüşşebap State Hospital, Compulsory Internal Medicine Service
    • 2010 to 2013 – Bülent Ecevit University, Medical Oncology Specialization
    • 2013 to 2015 – Recep Tayyip Erdoğan University, Medical Oncology Compulsory Service
    • 2015 to Present – Associate Professor, Recep Tayyip Erdoğan University
    • 2015 to 2021 – Lecturer, Medical Oncology, Sakarya University Faculty of Medicine
    • 2020 to Present – Professor, Sakarya University Faculty of Medicine
    • 2020 to Present – Ph.D. Student, Inorganic Chemistry, Sakarya University

    Experience

    • 2008 – Cleveland Clinic, Rheumatology & Gastroenterology Rotation
    • 2016 to 2017 – Northeastern University, The Center for Pharmaceutical Biotechnology and Nanomedicine, Boston, U.S.

    Professional Memberships

    • TTOD (Turkish Society of Medical Oncology)
    • ASCO (American Society of Clinical Oncology)
    • ESMO (European Society for Medical Oncology)
  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Hasan Atilla Ozkan

  • 5 Eccellente 1 recensioni
  • 23 anni di esperienza
  • Turchia, Istanbul, VM Medical Park Pendik Hospital
  • Education & Expertise

    • 1997 | Hacettepe University Faculty of Medicine – Medical Degree
    • 2003 | Uludağ University Faculty of Medicine – Internal Medicine Specialization
    • 2007 | Uludağ University Faculty of Medicine – Hematology Subspecialty

    Professional Experience

    • 1998 (May – September) | Practitioner, Dr. Salaha Health Center, Rize
    • 1998 to 2003 | Research Assistant, Uludağ University Faculty of Medicine, Internal Medicine Department
    • 2003 to 2007 | Hematology Subspecialist, Uludağ University Faculty of Medicine, Hematology Division
    • 2007 to 2011 | Hematology Specialist, Bursa Ali Osman Sönmez Oncology Hospital (Compulsory Service)
    • 2011 to 2013 | Hematology Specialist, Private Anadolu Health Center Bone Marrow Transplant Center, Gebze
    • 2014 to 2015 | Assistant Professor, Yeditepe University Faculty of Medicine, Department of Internal Medicine
    • 2015 to 2020 | Associate Professor, Yeditepe University Faculty of Medicine, Department of Internal Medicine
    • 2020 to Present | Professor, Yeditepe University Faculty of Medicine, Department of Internal Medicine

    Courses & Certifications

    • Autologous and Allogeneic Stem Cell Transplantation Certificate
    • Clinical Phytotherapy Application Certificate
    • Flow Cytometry Experience Certificate
    • EBMT Stem Cell Transplantation Course

    Professional Memberships

    • Turkish Medical Chamber
    • Turkish Hematology Association (Full Member, No: 893)
    • Turkish Therapeutic Apheresis Association (Current President)
    • Geriatric Hematology Association
    • Hematological Oncology Association
    • EBMT (European Bone Marrow Transplantation)

    Awards & Recognitions

    • 2011 | 6th Turkish Therapeutic Apheresis Congress – Young Researcher Award
  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Yusuf Acikgoz

  • Medico leader per Chemioterapia
  • 4.9 Eccellente 7 recensioni
  • 10 anni di esperienza
  • Turchia, Ankara, Lokman Hekim University Ankara Hospital
  • Associate Professor Dr. Yusuf AÇIKGÖZ
    Specialization: Medical Oncology

    Education:

    • 2004-2011: İnönü University Faculty of Medicine
    • 2011-2016: Ankara Numune Training and Research Hospital, Internal Medicine
    • 2017-2022: Health Sciences University, Medical Oncology

    Professional Experience:

    • 2016-2017: Bingöl City Hospital, Internal Medicine
    • 2021-2022: Health Sciences University, Medical Oncology
    • 2022-2023: Kastamonu Education and Research Hospital, Medical Oncology
    • 2023-2024: Ohio State University, Medical Oncology
    • 2024-Present: Lokman Hekim University, Medical Oncology, Ankara Hospital

    Clinical Trials, Courses, Certifications:

    Clinical Trials:

    • 2017-2021: Phase III, CheckMate-649 Study (Assistant Investigator)
    • 2022-Present: Phase III, Fortitude-101 Study (Assistant Investigator)

    Courses:

    • 2018: Medicres Basic and Advanced Biostatistics Training Program (ongoing), Istanbul-Vienna
    • 2019: Immuno-Oncology Education Course, March 1-2, 2019, Vienna, Central European Cooperative Oncology Group (CECOG)
    • 2018: Good Clinical Practice Certification, April 7-8, 2018, Ankara, Health Sciences University
    • 2017: Basic Oncology Training Program, November 25-26, 2017, Adana, Clinical Oncology Society
    • 2016: Basic Ultrasonography Course (10 hours theoretical + 10 hours practical), September 24-25, 2016, Ankara, Turkish Emergency Medicine Association

    Certifications:

    • Ongoing: ECFMG Certification
    • 2024: CITI Responsible Conduct of Research (The Ohio State University)
    • 2024: CITI IACUC-Laboratory Animal Research (The Ohio State University)
    • 2024: CITI Human Subjects Protection (The Ohio State University)
    • 2024: CITI Good Clinical Practice (The Ohio State University)
    • 2023: Occupational English Test (OET)
    • 2019: International English Language Testing System (IELTS), Total Score: 6.5, May 26, 2019, Ankara, British Council
    • 2017: USMLE Step 2 CK Exam; Score: 244, February 7, 2017
    • 2016: USMLE Step 1 Exam; Score: 215, August 25, 2016

    Memberships:

    • American Society of Clinical Oncology (ASCO) - 2022
    • Turkish Society of Medical Oncology - 2020
  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Axel Stang

  • 4.6 Eccellente 130 recensioni
  • 30 anni di esperienza
  • accreditamenti:
  • Germania, Amburgo, Asklepios Hospital Barmbek
  • Dr. Axel Stang is a professor, Head Physician of Asklepios Barmbek Clinic, with a specialization in internal medicine, oncology, and hematology. He conducts antibody and molecular therapies to reduce tumor size, and is a member of multiple organizations and societies. Dr. Stang has published articles on the effectiveness of radiofrequency ablation in treating of metastatic colon cancer, and was a member of a research group that studied the effects of liver embolization. Patients can submit a request on the Bookimed website to get a consultation with the professor.

  • Mostra di più
Chemioterapia
$3,116.45 - $5,194.08
Informazioni

Irfan Cicin

  • 5 Eccellente 1 recensioni
  • 29 anni di esperienza
  • Turchia, Istanbul, İstinye University Liv Hospital Topkapı
  • Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

    Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

    Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Nail Paksoy

  • 4.5 Buono 2 recensioni
  • 15 anni di esperienza
  • accreditamenti:
  • Turchia, Istanbul, Medipol Bahçelievler Hospital

  • PROFESSIONAL EXPERIENCE

    2011-2012
    Erzurum Koprukoyu State Hospital
    Department: General Medicine

    2012-2017
    Istanbul University Cerrahpaşa Medical Faculty
    Department: Internal Medicine

    06/2017-10/2017
    Istanbul Gaziosmanpasa Taksim Training and Research Hospital
    Department: Internal Medicine

    10/2017-11/2018
    Istanbul University Istanbul Medical Faculty
    Department: Allergy and Immunology Fellowship

    2018/2022
    Istanbul University Oncology Institute
    Department: Medical Oncology Fellowship

    2022-2023
    Tekirdag City Hospital
    Department: Medical Oncology Specialist

    2023-present
    Istanbul Medipol University Medipol Bahcelievler Private Hospital
    Department: Medical Oncology Assoc. Prof.

     

    EDUCATION

    2005-2011
    Medical Education
    Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

    2012-2017
    Internal Medicine
    Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

    2017-2018
    Allergy-Immunology Fellowship
    Istanbul University Istanbul Medical Faculty
    Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

    2018-2022
    Medical Oncology Fellowship
    Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

    2022
    ESMO Board Certification in Medical Oncology
    10th September 2022 in Paris, France.

    2023
    Medical Oncology Assoc. Prof.
    Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

     

    INTERNATIONAL CLINICAL TRIALS:

    1. Astefania - ROCHE

    • Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
    • Role: Subinvestigator

    2. PFİZER

    • Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
    • Role: Subinvestigator

    3. RECITE - AMGEN

    • Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
    • Role: Subinvestigator

    4. NAVIGATE - BAYER

    • Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
    • Role: Subinvestigator

    5. RUBY - Tesaro (PRA)

    • Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
    • Role: Subinvestigator

    6. ENGOT-ov43/GOG-3036 - MSD

    • Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
    • Role: Subinvestigator

    7. ASTRA ZENECA

    • Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
    • Role: Subinvestigator

    8. ROSY-O - ASTRA ZENECA

    • Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
    • Role: Subinvestigator
    •  

    INTERNATIONAL PUBLICATIONS

    I. Published journal articles indexed by SCI, SSCI, and AHCI

    Weekly Paclitaxel in Classic Kaposi Sarcoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
    • Journal: Medicine, 102(5)

    Carboplatin Desensitization in Ovarian Carcinoma

    • Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
    • Journal: Medicine, 101(45), e31726

    High-Dose Chemotherapy for Ewing’s Sarcoma

    • Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
    • Journal: Medicine, 101(49), e32213

    Multidrug Refractory TFE3(+) Renal Cell Carcinoma

    • Authors: Paksoy, Nail, et al.
    • Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

    Crizotinib Efficacy in NSCLC with MET Alterations

    • Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
    • Journal: Medicine, 101(50), e32368

    Clinicopathological Features in ALK Mutant NSCLC

    • Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
    • Journal: Medicine, 101(34)

    PSMA-Based Tumor Burden in Prostate Cancer

    • Authors: HAS SIMSEK, Duygu, et al.
    • Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

    Atezolizumab in Metastatic Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: European Urology Focus, 2021, 7.5: 1061-1066

    Pulmonary Sarcomatoid Carcinoma

    • Authors: FERHATOGLU, Ferhat, et al.
    • Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

    Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

    • Authors: TURAL, Deniz, et al.
    • Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

    Atezolizumab with Chemotherapy in Small Cell Lung Cancer

    • Authors: GÜRBÜZ, Mustafa, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

    FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

    • Authors: AY, Seval, et al.
    • Journal: Journal of Chemotherapy, 2022, 1-7

    Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

    • Authors: CIL, Ibrahim, et al.
    • Journal: Tumori Journal, 2022, 108.1: 19-25

    Real-Life Efficacy of Osimertinib in Advanced NSCLC

    • Authors: HIZAL, Mutlu, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

    ALK-Positive Cells Percentage and Alectinib Efficacy

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
    • Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

    Real-World Data on Alectinib in ALK-Positive NSCLC

    • Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
    • Journal: Future Oncology, 18(23), 2573-2582

    Prognostic Factors in Metastatic RCC with T790M Mutation

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

    • Authors: DEMIR, Semra, et al.
    • Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

    Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

    • Authors: ÖZDEMIR, Seçil Kepil, et al.
    • Journal: Allergy, 2019, 74.6: 1187-1190

    Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

    • Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
    • Journal: The Oncologist, oyad257

    Subsequent Treatments in Hormone-Positive Breast Cancer Progression

    • Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
    • Journal: BMC cancer, 23(1), 192

    Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
    • Journal: Scientific Reports, 13(1), 8779

    Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

    • Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
    • Journal: Journal of Cancer Research and Clinical Oncology, 1-9

    Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

    • Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
    • Journal: European Journal of Breast Health, 19(2), 128

    Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

    • Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
    • Journal: Future Oncology, 19(10), 727-736

    Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

    • Authors: Dogan, I., Paksoy, N., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

    • Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
    • Journal: Journal of Cancer Research and Therapeutics

    FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

    • Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
    • Journal: Journal of Cancer Research and Therapeutics

    Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

    • Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
    • Journal: [Not specified]

    Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

    • Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
    • Journal: Medicine, 102(39), e35383

    Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

    • Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
    • Journal: Medicine, 102(41), e35245

    Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

    Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

    Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

    Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

    Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

    Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

    Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

    Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

    Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

    Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

    Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

    Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

    Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

     

    Thesis:

    Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

    International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

    Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

    • Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

    Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

    • Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

    Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

    • Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

    Efficacy of temozolomide in pretreated patients with metastatic sarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

    • Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

    Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

    • Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

    Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

    • Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

    Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

    • Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

    Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

    • Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

    Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

    • Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

     

     

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Atakan Topcu

  • 5 Eccellente 3 recensioni
  • 13 anni di esperienza
  • Turchia, Istanbul, Medipol Acibadem District Hospital
  • Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

    He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

    Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Tarik Salman

  • Nuova
  • 32 anni di esperienza
  • Turchia, Smirne, Medicalpoint International Hospital
  • Diseases

    • Lung Cancer
    • Skin Cancers
    • Gastrointestinal Cancers
    • Genitourinary Cancers
    • Gynecological Cancers
    • Colon Cancer
    • Breast Cancer
    • Rare Cancers

    Treatment Methods

    • Individual Treatments (Comprehensive Genomic Profiling)
    • Targeted Therapies
    • Immunotherapy
    • Cancer Vaccines
    • Chemotherapy
    • Clinical Research/Experimental Medical Research

    Experience

    • 2017- 2024: Katip Çelebi University Faculty of Medicine Atatürk Education and Research Hospital Medical Oncology Clinic Associate Professor / Lecturer
    • 2022 December – 2023 March: Academic visitor Moffitt Cancer Center Cutaenous Oncology Clinic Tampa, Florida USA
    • 2013- 2017: Katip Çelebi University Faculty of Medicine Atatürk Training and Research Hospital – Medical Oncology Clinic Specialist Physician
    • 2012-2013: Izmir Education and Research Hospital, Medical Oncology Specialist Physician
    • 2012-2012: Mersin State Hospital, Medical Oncology Specialist Physician
    • 2010-2012: Dokuz Eylül University Faculty of Medicine, Department of Medical Oncology, Sub-branch Research Assistant
    • June-August 2008, December 2008 – February 2009: Memorial Sloan Kettering Cancer Center Observership programme
    • 2007-2009: Kartal Education and Research Hospital, Medical Oncology Sub-branch Research Assistant
    • 2006-2007: Siirt State Hospital, Internal Medicine, Specialist Physician
    • 2005-2006: Çukurova University Faculty of Medicine, Medical Oncology Sub-branch Research Assistant
    • 2004-2005: SSK Siirt Hospital, Internal Medicine Specialist Physician
    • 2003-2004: SSK Mardin Hospital, Internal Medicine Specialist Physician
    • 1998-2003: SSK Izmir Training and Research Hospital, 3rd Internal Medicine Clinic, Research Assistant
    • 1998-1998: SSK Izmir Training and Research Hospital Infectious Diseases Research Assistant
    • 1997-1998: Izmir Ataturk Training and Research Hospital, Anesthesiology and Reanimation Clinic, Research Assistant
    • 1995-1997: Şırnak Cizre Central Health Center
    • 1994-1995: Şırnak İdil Oyalı Village Health Center

    Professional Memberships

    • Turkish Society of Medical Oncology 2008 
    • (2018-2021 Term Board Member)
    • Izmir Oncology Group, Board Member (2014 -…)
    • Geriatric Oncology Association, Board Member (2015-…)
    • Mediterranean Oncology Association Board Member (2020 -…)
    • Turkish Biochemistry Association, Member, 2016
    • European Society of Medical Oncology, Member, 2012
    • American Society of Clinical Oncology, Member, 2008
  • Mostra di più
Visita dal medico
Prezzo su richiesta
Informazioni

Eckhart Weidmann

  • 4.5 Buono 52 recensioni
  • 36 anni di esperienza
  • Germania, Francoforte sul Meno, Nordwest Clinic (Krankenhaus)
  • Dr. Eckhart Weidemann is a highly experienced hematologist specializing in the treatment of non-Hodgkin lymphoma, with over 30 years of practice. He is the head of the Hematology sector at Nordwest Clinic.
  • Mostra di più
Chemioterapia
$2,885.6 - $4,963.23
Informazioni